Your browser is no longer supported. Please, upgrade your browser.
Settings
ARDX Ardelyx, Inc. daily Stock Chart
ARDX [NASD]
Ardelyx, Inc.
Index- P/E- EPS (ttm)-1.32 Insider Own10.40% Shs Outstand88.88M Perf Week1.45%
Market Cap608.28M Forward P/E- EPS next Y-1.08 Insider Trans-2.13% Shs Float87.94M Perf Month0.36%
Income-91.20M PEG- EPS next Q-0.26 Inst Own86.30% Short Float3.66% Perf Quarter21.88%
Sales6.50M P/S93.58 EPS this Y9.30% Inst Trans2.31% Short Ratio4.19 Perf Half Y-4.49%
Book/sh1.89 P/B3.71 EPS next Y-1.90% ROA-48.50% Target Price- Perf Year161.94%
Cash/sh2.58 P/C2.73 EPS next 5Y30.00% ROE-77.20% 52W Range2.10 - 8.81 Perf YTD-6.46%
Dividend- P/FCF- EPS past 5Y-53.50% ROI-38.70% 52W High-20.36% Beta1.99
Dividend %- Quick Ratio9.80 Sales past 5Y-30.10% Gross Margin90.80% 52W Low234.29% ATR0.46
Employees88 Current Ratio9.80 Sales Q/Q- Oper. Margin- RSI (14)51.94 Volatility7.07% 6.53%
OptionableYes Debt/Eq0.30 EPS Q/Q39.80% Profit Margin- Rel Volume0.78 Prev Close7.02
ShortableYes LT Debt/Eq0.26 Earnings- Payout- Avg Volume769.74K Price7.02
Recom1.30 SMA202.49% SMA50-1.94% SMA2007.40% Volume0 Change0.00%
Feb-18-20Resumed Jefferies Buy $11
Feb-12-20Initiated Citigroup Buy $13
Feb-10-20Initiated Cowen Outperform
Apr-08-19Initiated Piper Jaffray Overweight $15
Aug-24-18Initiated Jefferies Buy $7
Mar-19-18Resumed Leerink Partners Outperform $13
Nov-29-17Reiterated Citigroup Buy $16 → $17
Nov-22-17Reiterated Ladenburg Thalmann Buy $19 → $16
Oct-17-17Resumed Leerink Partners Outperform
Mar-31-16Initiated Ladenburg Thalmann Buy
Mar-09-16Initiated Cantor Fitzgerald Buy $19
Mar-03-16Initiated Citigroup Buy
Jun-30-20 08:00AM  
Jun-28-20 08:30AM  
Jun-19-20 12:45PM  
Jun-15-20 08:00AM  
Jun-09-20 08:45PM  
Jun-08-20 04:01PM  
May-26-20 09:00AM  
May-21-20 05:23PM  
May-18-20 04:01PM  
May-12-20 10:44AM  
May-11-20 12:00PM  
May-10-20 08:16AM  
May-07-20 04:02PM  
Apr-28-20 12:00PM  
Apr-23-20 06:14AM  
Apr-17-20 07:30AM  
Mar-16-20 09:00AM  
Mar-09-20 08:15AM  
Mar-06-20 05:15PM  
04:02PM  
Feb-26-20 12:30PM  
08:00AM  
Feb-19-20 08:00AM  
Dec-31-19 05:16AM  
Dec-05-19 07:14AM  
Dec-04-19 11:32PM  
04:56PM  
07:06AM  
Dec-03-19 08:18AM  
07:45AM  
07:25AM  
Dec-02-19 04:01PM  
Nov-27-19 07:26AM  
Nov-26-19 04:00PM  
08:06AM  
Nov-25-19 06:00PM  
Nov-06-19 04:05PM  
04:02PM  
Nov-01-19 06:13AM  
Oct-10-19 04:00PM  
Sep-26-19 08:20AM  
Sep-19-19 02:31PM  
Sep-17-19 04:01PM  
Sep-13-19 12:29PM  
11:08AM  
08:24AM  
07:40AM  
Sep-12-19 03:12PM  
07:38AM  
Sep-11-19 05:47PM  
Sep-04-19 04:42PM  
12:07PM  
12:00PM  
10:31AM  
10:02AM  
07:08AM  
Sep-03-19 10:56AM  
08:00AM  
Sep-02-19 04:00PM  
Aug-21-19 01:06PM  
Aug-19-19 06:00AM  
Aug-09-19 09:25AM  
08:00AM  
Jul-30-19 10:38AM  
Jul-09-19 01:49PM  
Jun-25-19 08:33PM  
May-30-19 09:00AM  
May-16-19 12:56PM  
May-07-19 06:45PM  
05:34PM  
04:02PM  
10:30AM  
May-06-19 09:55AM  
Apr-10-19 12:33PM  
Mar-19-19 05:38PM  
Mar-14-19 05:00PM  
Mar-07-19 05:00PM  
Mar-06-19 04:05PM  
Mar-01-19 02:54PM  
Feb-21-19 08:00AM  
Feb-12-19 08:25AM  
Feb-07-19 06:30AM  
Jan-18-19 09:20AM  
Dec-18-18 02:50AM  
Nov-26-18 02:26PM  
Nov-13-18 08:30AM  
Nov-07-18 06:12PM  
04:05PM  
Oct-26-18 01:01PM  
Oct-16-18 07:50AM  
Oct-08-18 08:01AM  
Oct-04-18 06:30AM  
Sep-18-18 08:19AM  
Sep-13-18 06:30AM  
Aug-29-18 02:16PM  
Aug-17-18 01:40PM  
08:20AM  
Aug-07-18 04:51PM  
04:01PM  
02:30PM  
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MOTT DAVID MDirectorJun 25Buy6.9668,373476,040247,284Jun 26 04:19 PM
MOTT DAVID MDirectorJun 24Buy6.7572,598489,862178,911Jun 26 04:19 PM
MOTT DAVID MDirectorJun 22Buy6.754,67331,525106,313Jun 24 06:49 PM
BASKETT FOREST10% OwnerJun 15Sale6.37432740Jun 17 04:00 PM
SANDELL SCOTT D10% OwnerJun 15Sale6.37432740Jun 17 04:00 PM
BASKETT FOREST10% OwnerJun 12Sale6.4244,992288,68243Jun 12 05:38 PM
SANDELL SCOTT D10% OwnerJun 12Sale6.4244,992288,68243Jun 12 05:40 PM
SANDELL SCOTT D10% OwnerJun 11Sale6.3244,991284,46545,035Jun 12 05:40 PM
BASKETT FOREST10% OwnerJun 11Sale6.3467,891430,3330Jun 12 05:38 PM
RAAB MICHAELPresident & CEOJun 01Sale7.3323,128169,63546,257Jun 02 06:38 PM
RAAB MICHAELPresident & CEOMay 05Sale7.034,48631,53669,385May 05 06:11 PM
RAAB MICHAELPresident & CEOMay 04Sale7.0115,941111,68673,871May 05 06:11 PM
GRAMMER ELIZABETH ASee RemarksApr 27Sale7.4717,824133,173101,608Apr 28 04:43 PM
RAAB MICHAELPresident & CEOApr 17Sale7.029,42866,16989,812Apr 17 08:01 PM
RAAB MICHAELPresident & CEOApr 16Sale7.0110,50073,64299,240Apr 17 08:01 PM
RAAB MICHAELPresident & CEOApr 15Sale7.035003,515109,740Apr 17 08:01 PM
RAAB MICHAELPresident & CEOMar 02Option Exercise1.0811,12312,013219,180Mar 04 08:12 PM
RAAB MICHAELPresident & CEOMar 02Sale7.0120,428143,284110,240Mar 04 08:12 PM
RAAB MICHAELPresident & CEOMar 02Sale7.0011,12377,861208,057Mar 04 08:12 PM
RAAB MICHAELPresident & CEOFeb 05Option Exercise1.0825,00027,000231,828Feb 07 06:49 PM
RAAB MICHAELPresident & CEOFeb 05Sale7.3225,000182,928206,828Feb 07 06:49 PM
GRAMMER ELIZABETH AEVP, General CounselDec 30Buy7.51664962,066Jan 02 08:22 PM
GRAMMER ELIZABETH AEVP, General CounselDec 03Option Exercise3.425,00017,100123,219Dec 05 04:37 PM
GRAMMER ELIZABETH AEVP, General CounselDec 03Sale8.005,00040,000118,219Dec 05 04:37 PM
GRAMMER ELIZABETH AEVP, General CounselNov 19Option Exercise3.425,00017,100123,219Nov 21 07:17 PM
GRAMMER ELIZABETH AEVP, General CounselNov 19Sale7.005,00035,000118,219Nov 21 07:17 PM
Kaufmann MarkChief Financial OfficerOct 07Option Exercise0.5420,00010,800161,418Oct 08 05:37 PM
Kaufmann MarkChief Financial OfficerOct 07Sale4.5620,00091,190141,418Oct 08 05:37 PM
GRAMMER ELIZABETH AEVP, General CounselAug 22Sale3.509483,318115,890Aug 23 04:06 PM
GRAMMER ELIZABETH AEVP, General CounselAug 21Sale3.504,05214,182116,838Aug 23 04:06 PM